The Adaptive COVID treatment trial (ACTT) is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19.  This podcast discusses what’s next by introducing baricitinib and the ACTT-2 Trial Design.  To learn more about the clinical experience with remdesivir, supportive care for COVID-19 patients, and discussion of remdesivir clinical trial results from the Pharmacy Team at Nebraska Medicine, please see the full webinar recording at ASHP elearning.org.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.